Follow up of Low-risk GTN is done for
**Question:** Follow up of Low-risk GTN is done for
A. 72 hours
B. 96 hours
C. 120 hours
D. 168 hours
**Core Concept:**
Garbaggio Toxemia is a condition characterized by the presence of fetal distress during labor, and it is often treated with glyceryl trinitrate (GTN). GTN is a nitrate medication that works by increasing blood flow to the uterus and placental bed, thereby improving oxygenation. In low-risk cases, the follow-up duration after GTN administration is crucial to determine the drug's effectiveness and monitor for any adverse effects.
**Why the Correct Answer is Right:**
In low-risk cases, the follow-up duration after GTN administration is crucial for assessing fetal wellbeing and monitoring the response to the therapy. GTN acts as a vasodilator, causing a reduction in maternal blood pressure, which may lead to maternal hypotension and bradycardia. Therefore, a longer follow-up period is required to ensure that maternal hemodynamics remain stable and the fetus remains adequately oxygenated.
**Why Each Wrong Option is Incorrect:**
A. 72 hours - A shorter follow-up period may not be sufficient to determine the drug's efficacy and monitor for adverse effects. Maternal hemodynamics and fetal wellbeing should be assessed regularly during this period.
B. 96 hours - Although longer than the correct answer, a 168-hour follow-up might be excessive for low-risk cases. The focus should be on ensuring stable maternal hemodynamics and adequate fetal oxygenation.
C. 120 hours - Similar to option B, a longer follow-up period than needed may lead to unnecessary clinical interventions and increased monitoring burden.
D. 168 hours - As mentioned earlier, a longer monitoring period than required may lead to unnecessary interventions and increased burden on both mother and healthcare system.
**Clinical Pearl:**
In low-risk cases of GTN therapy, a 72-hour follow-up period is appropriate to assess fetal wellbeing, maternal hemodynamics, and monitor for any adverse effects. This duration ensures that the drug's therapeutic efficacy is effectively evaluated without causing unnecessary interventions or monitoring burden.